National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

Rapid Review

Commenced Completed Outcome
12/02/2013 28/02/2013 Full Pharmacoeconomic Assessment not Recommended.